Reply to “Central hypopnea classification: bridging the gap between event identification and clinical utility” Authors: Anjali P Ahn, Atul Malhotra Published: 2026 We appreciate the interest of Dr. Kumari regarding our article entitled “The importance of classifying central hypopneas: a call to action” [1]. In her letter entitled, “Central hypopnea classification: bridging the gap between event identification and clinical utility,” Dr. Kumari notes that no quantitative threshold is proposed to guide clinical decision-making, and no evidence is provided to demonstrate the clinical consequences of hypopnea classification nor evidence of whether classification changes disease categorization, treatment response, or patient-centered outcomes [2]. We appreciate her highlighting the need for thresholds to define a clinically meaningful burden of central disease as well as the need for research regarding the impact of hypopnea classification on outcomes. Research in this area is lacking. As a field, we have not focused on classifying hypopneas, and hence, very little data exists, to our knowledge, to understand how hypopnea classification may impact disease categorization and treatment outcomes. The motivation behind our paper was exactly that—to highlight a need to better understand and classify these events. Given the emergence of mechanistically specific treatments, including pharmacotherapy and neurostimulation, proper classification of hypopneas may be critical to guide interventions while optimizing health outcomes for those afflicted with various conditions. Interestingly, as a field, we also struggle to identify an exact threshold for treatment of obstructive sleep apnea (OSA) using the well-established AHI. Treatment decisions are usually based on a combination of AHI, hypoxemia, clinical symptoms, and comorbidities. AHI is categorized as mild, moderate, or severe based on arbitrary/consensus, not biological, thresholds (< 5, 5–15, 15–30, > 30/h). Of note, AHI is a poor predictor of OSA complications in general; moreover, a clinically important improvement in AHI is challenging to define. Sleep apnea–specific hypoxic burden (SASHB) may do a better job at predicting mortality and cardiovascular disease than AHI, although again minimal data are available to establish SASHB as a validated surrogate measure. The optimum metrics for studies in sleep disordered breathing likely vary with the outcome of interest, and treatment decisions are often guided, in part, by patient preferences. Our manuscript is not meant to be prescriptive, but rather to raise awareness and highlight a need for research, reflection, and discussion. We discuss several methods for classifying hypopneas which need further validation and outcome studies, and as a field, we need to understand better the impact of classifying these respiratory events. The scientific process will take time, but there was broad agreement among the authors of our manuscript that investigation regarding hypopnea classification and how it changes management are important to pursue. We appreciate that Dr. Kumari has helped raise awareness regarding these proposed next steps. Author contribution This manuscript was written by the corresponding author with editorial contributions by the last author. Funding There was no specific funding for this manuscript. Data availability Not applicable. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests AM is funded by NIH. He reports income from Eli Lilly, Livanova, Zoll, Powell Mansfield, and Sunrise. He is co-founder and has equity in Clairyon, a small startup related to predictive analytics. Resmed gave a philanthropic donation to UCSD. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Not applicable.